Medivir AB (Nasdaq Stockholm: MVIR), a Sweden-based pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced on Monday that it has named Pia Baumann MD, PhD as its new chief medical officer (CMO) effective 20 February 2023.

In the new role, Dr Baumann will be responsible for the continued clinical development of the candidate drug fostroxacitabine bralpamide (fostrox) and will be part of the firm's management team.

Dr Baumann has served on various clinical work at Karolinska Hospital and larger pharmaceutical companies and smaller biotech companies, where she has developed global product strategies and designed and carried out clinical studies in partnership with leading clinics. She has served as vice president Medical with global responsibility for the company's Tagrisso and Lung Cancer franchise at AstraZeneca. She has served in leading, global positions in cancer drug development at Takeda, Incyte and ARIAD Pharmaceuticals.